noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Serina Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)
City of Vista, CA

City of Vista Statement on Moonlight Amphitheatre Concessions RFP
Fiscalnote Holdings Inc.

FiscalNote Expands Access to Its U.S. Policy Intelligence Across Asian[...]

Healthcare

Kirkland & Ellis LLP

03/20/2026 | Press release | Distributed by Public on 03/20/2026 11:03

Kirkland Advises HarbourVest on Lead Investment in $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals

Kirkland & Ellis advised HarbourVest Partners, LLC as the lead investor in QHP Capital L.P.'s $1.1 billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity's long-term value creation plan.

Read the transaction press release

The Kirkland team included investment funds lawyers Tarsis Goncalves, Joseph Salvatore, Brandon Barrett and Sam Bialczak; tax lawyer Elie Zolty; and antitrust & competition lawyer Rebekah Tobison Scherr.

Kirkland & Ellis LLP published this content on March 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 20, 2026 at 17:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format